Literature DB >> 30786193

Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer.

Giancarlo Agnelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30786193     DOI： 10.1056/NEJMe1816060

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

Review 1.  Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet?

Authors:  Tulsi Patel; David A Iglesias
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

2.  Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews.

Authors:  Emanuel Raschi; Matteo Bianchin; Milo Gatti; Alessandro Squizzato; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

3.  New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting.

Authors:  Jiangyang Du; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-07       Impact factor: 2.859

Review 4.  The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.

Authors:  Tzu-Fei Wang; Jeffrey I Zwicker; Cihan Ay; Ingrid Pabinger; Anna Falanga; Darko Antic; Simon Noble; Alok A Khorana; Marc Carrier; Guy Meyer
Journal:  J Thromb Haemost       Date:  2019-07-28       Impact factor: 5.824

5.  What's new in the prevention and treatment of cancer-associated thrombosis?

Authors:  Miriam Kimpton; Marc Carrier
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score.

Authors:  Lucy A Norris; Mark P Ward; Sharon A O'Toole; Zibi Marchocki; Nadia Ibrahim; Ali S Khashan; Feras Abu Saadeh; Noreen Gleeson
Journal:  Res Pract Thromb Haemost       Date:  2020-05-28

7.  Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.

Authors:  Kristen M Sanfilippo; Suhong Luo; Tzu-Fei Wang; Mark Fiala; Martin Schoen; Tanya M Wildes; Joseph Mikhael; Nicole M Kuderer; David C Calverley; Jesse Keller; Theodore Thomas; Kenneth R Carson; Brian F Gage
Journal:  Am J Hematol       Date:  2019-08-19       Impact factor: 10.047

8.  External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.

Authors:  Alex C Spyropoulos; Joanna B Eldredge; Lalitha N Anand; Meng Zhang; Michael Qiu; Soheila Nourabadi; David J Rosenberg
Journal:  Oncologist       Date:  2020-02-04

9.  Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial.

Authors:  Rick Ikesaka; Deborah Siegal; Ranjeeta Mallick; Tzu-Fei Wang; Deborah Witham; Carolyn Webb; Marc Carrier
Journal:  Res Pract Thromb Haemost       Date:  2021-05-05

10.  Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors.

Authors:  Noha Abdel-Wahab; Jean H Tayar; Faisal Fa'ak; Gaurav Sharma; Maria A Lopez-Olivo; Abdelrahman Yousif; Tasneam Shagroni; Sami Al-Hawamdeh; Cristhiam M Rojas-Hernandez; Maria E Suarez-Almazor
Journal:  Blood Adv       Date:  2020-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.